Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Assets (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Current Assets for 6 consecutive years, with $28.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 56.21% year-over-year to $28.8 million, compared with a TTM value of $28.8 million through Sep 2025, down 56.21%, and an annual FY2024 reading of $55.9 million, down 48.96% over the prior year.
  • Current Assets was $28.8 million for Q3 2025 at Ovid Therapeutics, down from $42.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $236.7 million in Q1 2021 and bottomed at $28.8 million in Q3 2025.
  • Average Current Assets over 5 years is $120.1 million, with a median of $109.6 million recorded in 2023.
  • The sharpest move saw Current Assets soared 389.39% in 2021, then crashed 56.21% in 2025.
  • Year by year, Current Assets stood at $190.5 million in 2021, then tumbled by 31.03% to $131.4 million in 2022, then fell by 16.58% to $109.6 million in 2023, then tumbled by 48.96% to $55.9 million in 2024, then tumbled by 48.47% to $28.8 million in 2025.
  • Business Quant data shows Current Assets for OVID at $28.8 million in Q3 2025, $42.1 million in Q2 2025, and $45.9 million in Q1 2025.